Alembic receives FDA nod for generic Pataday
Alembic has received the Food and Drug Administration’s clearance for olopatadine hydrochloride ophthalmic solution, 0.2%.
The product is the generic of Novartis’s Pataday ophthalmic solution 0.2%. It is indicated for the treatment of ocular itching associated with allergic conjunctivitis.
Olopatadine hydrochloride ophthalmic solution, 0.2% had a market value of $62 million for the 12 months ending December 2018, according to IQVIA data.
The product is the generic of Novartis’s Pataday ophthalmic solution 0.2%. It is indicated for the treatment of ocular itching associated with allergic conjunctivitis.
Olopatadine hydrochloride ophthalmic solution, 0.2% had a market value of $62 million for the 12 months ending December 2018, according to IQVIA data.